Click on the paperclip at the top of the page to add, Click on the paperclip at the top of the page to add, remove or edit files. If possible, please add a row to the table below to allow easy access to your slides.
Meeting date | Uploaded by | Slides | Comments |
---|---|---|---|
2 May 2012 | Julie | PFIM Interface 3.1 - cours M2R 10-11.pdf | |
15 May 2012 | Angelina | ||
6 June 2012 | Joe | ||
13 June 2012 | Joanna | EMA geriatric workshop - March 2012 - Shepard (submitted 19March).ppt | Terry Shepard's Slides |
12 October 2012 | Rollo | ||
9 November 2012 | Joanna | ||
13 November 2012 | Julie | ||
14 December 2012 | Lilia | Modelling neutrophil dynamics in children following bone marrow transplant | |
22 Februrary 2013 | Allienor Berges | ||
1 March 2013 | Rollo | ||
28 May 2013 | Charlotte |
9 May 2012 | PUW1 | Joanna | Immunology |
16 May 2012 | WCJ | Angelina | Zidovudine PK/PG |
23 May 2012 | PUW2 | Jig | LMWH in pregnancy |
30 May 2012 | No meeting | ||
6 June 2012 | PUW1 | Joe | Antimicrobial PKPD |
13 June 2012 | PUW1 | Terry Shepard | Geriatric PKPD |
20 June 2012 | PUW2 | Rollo/Joanna | Immunology modelling |
27 June 2012 | No meeting | ||
4th July 2012 | No meeting | ||
11th July 2012 | PUW2 | Julie | PAGE review |
18th July 2012 | PUW2 | Katie | Gentamicin in burns |
12/10/12 1pm | WCA | Rollo | Modelling of the immune reconstitution post BMT |
19/10/12 1pm | PUW3 | Joe | Prague Biometrics 2012;68:902-11 |
26/10/12 1pm | PUW3 | Charlotte | NAPPA (Beta lactam pharmacokinetics/pharmacodynamics) plans |
2/11/12 1pm | PUW3 | Eva | Neogent (developing Bayesian therapeutic drug monitoring) progress |
9/11/12 1pm | PUW3 | Joanna | Inference methods course review |
16/11/12 1pm | PUW2 | General discussion | |
23/11/12 1pm | PUW3 | Julie | Covariate selection methods in pharmacokinetic modelling |
30/11/12 1pm | PUW3 | Julie | NCA versus modelling in phase I studies for drugs with long half-life |
7/12/12 1pm | PUW3 | Goldacre talk | |
14/12/12 1pm | PUW3 | Lilia | Neutropenia post-BMT |
...
1/9/14 | LGSR | Joe | Antimicrobial PKPD IDM_clinpharm_Standing_2014.pdf |
8/9/14 meeting starts 2pm | Levinski | Julie | DDMore language |
15/9/14 | LGSR | Paul | Pharmacogenetics of diclofenac |
22/9/14 | LGSR | Yucheng | Count data models and introduction to Pirana |
29/9/14 | LGSR | Andreas | Gabapentin PKPD in paediatric neuropathic pain |
6/10/14 | LGSR | Liana | Tyrosine kinase inhibitor effects in polycystic kindney disease |
13/10/14 | LGSR | Joanna | |
20/10/14 | LGSR | Rollo | Short-term neutrophil and lymphocyte HSCT models |
27/10/14 | LGSR | Eva | NeoGent PKUK practice |
3/11/14 | LGSR | Seb | Item Response Theory: Application to NLME |
10/11/14 | LGSR | Joe | A new mechanistic model for antiretroviral pharmacodynamics |
17/11/14 | LGSR | Alberto | Anaesthesia depth with 3 different EEG measures |
24/11/14 | LGSR | Suzanne Reeves | Mechanisms underpinning antipsychotic sensitivity in Alzheimer's disease |
1/12/14 | LGSR | Deji | Mixed Effect Modelling in Hep C-HIV coinfected children |
8/12/14 meeting starts at 2pm | LGSR | TBC | To be confirmed |
15/12/14 | LGSR | Morris | Understanding the determinants of drug exposure and pharmacokinetic variability in tuberculosis patients |
...
7/9/15 | PUW3 | Aiwei | Dexmeditomidine PKPD |
14/9/15 | PUW3 | Eva | Meropenem in late onset sepsis and meningitis in neonates |
21/9/15 | PUW3 | Ludo | Dexmeditomidine PKPD (in veterinary subjects) |
28/9/15 | PUW3 | Ben | Modelling HCMV |
5/10/15 | PUW1 | Suzanne | Amisulpride PK update |
12/10/15 | PUW1 | David Moore | PKPD in TB |
19/10/15 | PUW1 | Joe | Personalised medicine with PKPD |
26/10/15 | PUW1 | Imperial Group | Antimicrobial decision support |
2/11/15 | PUW1 | ||
9/11/15 | PUW2 | Rollo | PhD viva prep talk |
16/11/15 | PUW2 | Eva | IRT for neonatal sepsis |
23/11/15 | PUW2 | Frank | PKPD in malaria |
30/11/15 | PUW2 | Morris | PBPK Modelling in TB |
7/12/15 | PUW2 | Liana | PKD PKPD |
14/12/15 | PUW2 | Pratima Chowdary | Individualised dosing in haemophilia |
Date
Location* | Presenter | Topic | |
---|---|---|---|
1/2/16 | PUW3 | Deji | HIV models in children |
4/4/16 | PUW2 | Morris | Model-based translational research in tuberculosis |
4/7/16 | PUW2 | Albert | SiRNA PD in neuroblastoma |
6/2/16 | PUW1 | Charlotte | Update on NAPPA |
6/6/16 | PUW2 | No meeting | PAGE |
7/3/16 | PUW3 | Frank | In vitro TB PD |
9/5/16 | PUW3 | Joy Dawes | Morphine and dexmeditomidine PK in children |
11/4/16 | PUW3 | Oliver Stirrup | Adult NLME in HIV under HAART |
11/7/16 | PUW2 | No Meeting | To be rescheduled: Min - NAPPA amoxicillin/co-amoxiclav PK results |
13/6/16 | PUW2 | Georgie | Flucloxacillin PK: Neonatal results from NAPPA |
14/3/16 | PUW3 | Julie | Bayesian inference in high-throughput pharmacogenetics |
15/2/16 | PUW3 | Yucheng | Count data modelling of BATA |
16/5/16 | PUW3 | Julie | Joint modelling of plasmatic and intracellular concentrations of Tenofovir (TDF) and Emtricitabine (FTC) - The COPHAR3 trial |
18/1/16 | PUW3 | Planning meeting | |
18/4/16 | PUW3 | Ben | Incorporating immunity into CMV models |
20/6/16 | PUW2 | Dan Wright | Model-based dose prediction: the curious case of allopurinol |
21/3/16 | PUW2 | Deji | Modelling poor immune response in HIV-infected children |
22/2/16 | PUW3 | Ben | CMV model update |
23/5/16 | PUW2 | Letizia | PBPK in TB |
25/1/16 | Levinski room | Joe | Scaling in PK and PD |
25/4/16 | PUW3 | Per Olsson | Life as a pharmacometrics consultant |
27/6/16 | PUW2 | Salvo | Neonatal antimicrobial PK |
29/2/16 | PUW2 | Fabrizia | PKPD in neurology |
...
Date | Location* | Presenter | Topic |
---|---|---|---|
19/12/16 (12:00) | PUW1 | Charlotte | Update on NAPPA |
16/1/17 | PUW4 | Frank | Practice MRC interview |
23/1/17 | PUW4 | Joe | FLACSAM PK results |
30/1/17 | PUW4 | All | Paediatric sample size discussion |
6/2/17 | PUW4 | Frank | Update on treosulfan/TB work |
13/2/17 | PUW4 | Mike and Sophida | MRes project outline |
20/2/17 | PUW2 | Ben | CMV PD |
27/2/17 | PUW2 | Charlotte | NAPPA update |
6/3/17 | PUW2 | Morris | Rationale for dose selection in tuberculosis: how to scale from mouse to human? |
13/3/17 | PUW2 | Benjamin Blaise | iSleep/iCare - real-time metabolic support for personalized intensive care |
20/3/17 | PUW2 | ||
27/3/17 | PUW2 | Aubrey Cunningham | Adjunctive therapy for severe malaria |
3/4/17 | PUW2 | Belen | PhD update |
10/4/17 | PUW2 | ||
24/4/17 | PUW1 | Annegret Dahlmann-noor | PKPD in ophthalmology |
8/5/17 | PUW1 | Paul Baverel | Tralokinumab, an investigational anti-IL13 monoclonal antibody: PK & exposure-response modeling to bridge adult and paediatrics clinical development plan |
15/5/17 | PUW1 | Morris | TB modelling PAGE practice |
22/5/17 | PUW1 | Ben | CMV modelling ESPID practice |
5/6/17 | PUW1 | No meeting | |
12/6/17 (12:00) | PUW3 | All | PAGE review |
19/6/17 | PUW1 | Ludo | HFIM progress |
26/6/17 | PUW1 | Maria Scarpa | End-user acceptability of orodispersible films (ODF) for delivery of medicine |
3/7/17 | PUW1 | ||
10/7/17 | PUW1 | ||
17/7/17 | PUW1 |
30/10/17 | Levinsky | ||
27/11/17 | Levinsky | Waty | Covariate analysis with supervised machine learning |
25/9/17 | PUW2 | Yomna | Treosulfan PK |
23/10/17 | Levinsky | ||
20/11/17 | Levinsky | Nicolas Fanget | Publishing in Nature journals |
18/12/17 | Levinsky | Ludo | HFIM modelling progress |
18/9/17 | Levinsky | Sophida | Posaconazole pharmacokinetics in children |
16/10/17 | Levinsky | Mandy W | Vitamin D PKPD plans |
13/11/17 | Levinsky | Shan Pan | Application of pharmacometrics in rheumatoid arthritis: case studies in clinical practice and drug development |
11/12/17 | Levinsky | Vicky | Rivaroxaban PKPD |
11/9/17 | Levinsky | no meeting | |
9/10/17 | Levinsky | ||
6/11/17 | Levinsky | Julie | PK of serum and intra cellular sustained-release Lithium |
4/12/17 | Levinsky | Julie | PK of total, unbound and intra cellular MPA |
2/10/17 | Levinsky | Ofran | Gender differences in infant mortality in UK PICUs |
8/1/18 | PUW 4 | planning meeting | |
15/1/18 | PUW 4 | Haifa | Posaconazole study protocol |
22/1/18 | PUW 4 | Frank | Vancomycin PKPD |
29/1/18 | PUW 4 | Dagan | Results from ABDose |
5/2/18 | PUW 4 | Shan | Salbutamol PKPD |
12/2/18 | PUW 4 | Dionna | CoMPLEX mini project |
19/2/18 | PUW 3 | ||
26/2/18 | PUW 3 | Bern | TB-PRACTECAL trial PK-PD study design |
5/3/18 | Levinski 12:00 start | Ayesha | Rituximab PKPD |
12/3/18 | PUW 3 | Ben | Statistical Challenges in T Cell Receptor Repertoire Immunophenotyping |
19/3/18 | PUW 3 | Joe | Posaconazole PK |
26/3/18 | PUW 1 | Waty | Machine learning approaches |
9/4/18 | PUW 3 | ||
16/4/18 | PUW 3 | planning meeting | |
23/4/18 | PUW 3 | no meeting ECCMID | |
30/4/18 | PUW 3 | Jig | Anticoagulant PKPD in haemodialysis |
14/5/18 | PUW 3 | Frank | Modelling progress in TB |
21/5/18 | PUW 3 | no meeting PK course | |
4/6/18 | PUW 3 | Maddlie | PhD introduction: PKPD modelling of sedative and analgesic effects |
11/6/18 | PUW 3 | Komal Bhatia | Infant growth in urban informal settlements (slums) in Mumbai, India |
18/6/18 | PUW 3 | Shan | Psoriasis PKPD modelling |
25/6/18 | PUW 3 | Oleg Volkov | Optimal design in PKPD |
2/7/18 | PUW 3 | Ben | CMV modelling |
9/7/18 | PUW 3 | Julie | Model-based bioequivalence |
3/9/18 | PUW 3 | planning meeting | |
10/9/18 | PUW3 | Frank | Modelling of in vitro antimicrobial experiments |
17/9/18 | PUW3 | no meeting | |
24/9/18 | PUW3 | Satveer | NIHR practice psoriasis TDM |
1/10/18 | PUW1 | Ofran | NIHR practice |
8/10/18 | PUW1 | Julie | Dynamic individual predictions of biomarker profiles and survival in Oncology with Stan, Monolix and Nonmem |
15/10/18 | PUW1 | ||
22/10/18 | PUW3 | Rashmi Kulkarni | Monitoring oxidative stress enables predictions of personalised glucose targets in diabetic patients |
29/10/18 | PUW3 | ||
5/11/18 | PUW3 | James Yates | Modelling nonclinical efficacy data for immune-oncology treatments |
12/11/18 | PUW3 | Frank | Vancomycin PKPD in children |
19/11/18 | PUW1 | John | PhD introduction - nlme in vaccine development |
26/11/18 | Levinski | Soumya | PhD introduction |
3/12/18 | PUW3 | Jaya | Neonatal vancomycin CSF PK |
10/12/18 | PUW3 | Daren Austin | Optimised dose for WHO weight bands |
7/1/19 | PUW3 | Planning meeting | |
14/1/19 | PUW3 | Joe | BSAC Antimicrobial chemotherapy meeting practice |
21/1/19 | PUW3 | ||
28/1/19 | PUW3 | Maddlie | Clonidine/fentanil PK update |
4/2/19 | PUW1 | journal club | |
11/2/19 | PUW1 | Frank | Predicting clinical outcome in TB |
18/2/19 | PUW1 | Charlotte | NAPPA overview |
25/2/19 | PUW3 | Phil Tresadern | popypkpd introduction |
4/3/19 | PUW3 | Silke | PhD work summary |
11/3/19 | PUW3 | Ferran | PK paper picking with ML |
18/3/19 | PUW3 | Maddlie | PKPD of sedation in neonates |
25/3/19 | PUW3 | Jude | PhD Introduction |
1/4/19 | PUW1 | Soumya | Rituximab PD in BMT |
8/4/19 | LEWINSKY | Zoe | PhD Introduction |
15/4/19 | PUW3 | no meeting | ECCMID |
13/5/19 | PUW3 | Claire Deakin | Modelling long-term outcomes and estimating treatment efficacy in a rare rheumatic disease |
20/5/19 | PUW3 | Haifa | Caspofungin PK in ECMO |
3/6/19 | PUW1 | ||
10/6/19 | LEVINSKY | no meeting | |
17/6/19 | PUW3 | All | PAGE review |
24/6/19 | PUW3 | Cintia | Paediatric Clinical Pharmacology in Buenas Aires |
1/7/19 | PUW3 | Wen Yao | PKPd in Malaysia |
8/7/19 | PUW3 | Joe | Treo PKPD |
15/7/19 | PUW3 | Maddlie | Upgrade practice |
Date | Location* | Presenter | Topic |
---|---|---|---|
2/9/19 | LGSR | Ferran | QSP machine learning practice |
12/9/19 [NOTE Thurs) | PUW2 | Palang Chotsiri and Richard Hoglund | Malaria PKPD |
16/9/19 | LGSR | Planning meeting | |
23/9/19 | LGSR | Simon | Peptide PKPD |
30/9/19 | LGSR | ||
7/10/19 | LGSR | ||
14/10/19 | LGSR | Julie | Pharmacogenomics and nlme - some applications |
21/10/19 | LGSR | Frank | TB PKPD |
28/10/19 | LGSR | Soumya | B cell reconstitution post HSCT and rituximab |
4/11/19 | LGSR | Ferran | PK parameter extraction with NLP |
11/11/19 | LGSR | Zoe | Fosfomycin PK in neonates |
18/11/19 | PUW2 | Joe | MRC interview practice |
25/11/19 | PUW1 | Maddlie | Clonidine PKPD in PICU |
2/12/19 | PUW2 | ||
9/12/19 | PUW2 | Silke | Antimicrobial PKPD |
16/12/19 | PUW2 | Zahra | Antimicrobial in vitro PKPD |
Date | Location* | Presenter | Topic |
7/9/20 | microsoft teams | Planning meeting | |
14/9/20 | microsoft teams | Joe | SARS-CoV-2 dynamics |
21/9/20 | microsoft teams | Soumya | B cell update |
28/9/20 | microsoft teams | Zoe | Upgrade practice |
5/10/20 | microsoft teams | Maddlie | EAPs conference practice |
12/10/20 | microsoft teams | Emma | EHR Prescribing patterns |
19/10/20 | microsoft teams | Jude | PhD progress update |
26/10/20 | microsoft teams | Mandy | Colecalciferol in children with chronic kidney disease |
2/11/20 | microsoft teams | Maddlie | SANNI update |
9/11/20 | microsoft teams | Silke | PTA of antimicrobials |
16/11/20 | microsoft teams | Haifa | Caspofungin PK in ECMO |
23/11/20 | microsoft teams | Zahra | Hollow fibre update |
30/11/20 | microsoft teams | Zoe | Benzinidazole |
7/12/20 | microsoft teams | Matt | Risperidone study |
14/12/20 | microsoft teams | Frank | TB |
21/12/20 | microsoft teams | James | PK/PD of MDR TB therapy |
microsoft teams |
Date | Location* | Presenter | Topic |
---|---|---|---|
4/1/21 | microsoft teams | Planning meeting | |
11/1/21 | microsoft teams | James | PKPD of MDR TB |
18/1/21 | microsoft teams | Ferran | PKPDai update |
25/1/21 | microsoft teams | Soumya | Rituximab PKPD |
1/2/21 | microsoft teams | Julie | TModel-based bioequivalence |
8/2/21 | microsoft teams | Ferran | PKPDai update |
15/2/21 | microsoft teams | Silke | Amp/gent update |
22/2/21 | microsoft teams | Saher | Teicoplanin pharmacokinetics |
1/3/21 | microsoft teams | Frank | Journal club |
8/3/21 | microsoft teams | Najla | PhD introduction |
15/3/21 | microsoft teams | Nadhia | |
29/3/21 | microsoft teams | Emma | Pre-upgrade |
12/4/21 | microsoft teams | planning meeting | |
19/4/21 | microsoft teams | Vijay Ivaturi | Pumasai |
26/4/21 | microsoft teams | ||
10/5/21 | microsoft teams | Jude | Tacrolimus update |
17/5/21 | microsoft teams | Soumya | B cell update |
24/5/21 | microsoft teams | Ludo | |
7/6/21 | microsoft teams | ||
14/6/21 | microsoft teams | Jude | Tacrolimus update |
21/6/21 | microsoft teams | Frank/Bern | TB trial |
28/6/21 | microsoft teams | Emma | Upgrade practice |
5/7/21 | microsoft teams | Zoe | Benzinidazole |
12/7/21 |
13/9/21 | microsoft teams | Planning meeting | |
20/9/21 | microsoft teams | Akosua | Mechanism based antimicrobial PKPD |
27/9/21 | microsoft teams | Zonghui | Vitamin D PKPD |
4/10/21 | microsoft teams | Soumya | B cell dynamics under anticancer therapies |
11/10/21 | microsoft teams | Quentin | Exploring the risk of AMR horizontal gene transfer by transduction in S. aureus during phage-antibiotic co-therapy |
18/10/21 | microsoft teams | Emma | Antimicrobial time series update |
25/10/21 | microsoft teams | ||
1/11/21 | microsoft teams | Fan | Favipiravir PKPD |
8/11/21 | microsoft teams | Zoe | PKPD of immunosuppressant-azole interactions |
15/11/21 | microsoft teams | Vicky | PKPD of rivaroxaban |
22/11/21 | microsoft teams | Zahra | Antimicrobial in vitro PD |
29/11/21 | microsoft teams | Frank | TB Practical |
6/12/21 | microsoft teams | Jude | Tacrolimus PKPD |
13/12/21 | microsoft teams | Najla | Fosfomycin in vitro PKPD |
12/1/22 | PUW4/ microsoft teams | Marie Sjölin Wijk | |
24/1/22 | PUW4/microsoft teams | Stefano | |
31/1/22 | PUW4/microsoft teams | Andrew Mead | |
7/2/22 | PUW3/microsoft teams | Hui | Machine learning based model fitting |
14/2/22 | PUW3/microsoft teams | Carol | Bivalirudin PKPD |
21/2/22 | PUW3/microsoft teams | Zoe | Posaconazole PKPD |
28/2/22 | PUW3/microsoft teams | Najla | Fosfomycin hollow fibre |
7/3/22 | PUW3/microsoft teams | Vicky Smith | Automated parameter extraction |
14/3/22 | PUW3/microsoft teams | Akosua | FLARE trial PKPD |
21/3/22 | PUW3/microsoft teams | Fan | Favipiravir PKPD |
28/3/22 | PUW3/microsoft teams | Emma | Antimicrobials update |
4/4/22 | PUW3/microsoft teams | ||
25/4/22 | PUW3/microsoft teams | Jude | Tacrolimus PKPD |
9/5/22 | PUW3/microsoft teams | Helen Shaw | Pharmacokinetic Challenges for a Children’s Medicine Company |
16/5/22 | PUW3/microsoft teams | ||
23/5/22 | PUW3/microsoft teams | Amanda Gwee | Paediatric PKPD down under |
6/6/22 | PUW3/microsoft teams | Zhonghui | Progress with GA modelling |
13/6/22 | PUW3/microsoft teams | Fan | Favi update |
20/6/22 | PUW3/microsoft teams | Soumya | B cell dynamics in BMT |
27/6/22 | PUW3/microsoft teams | Jamie Dean | Introducing the Computational Radiation Biology and Oncology Lab |
4/7/22 | PUW3/microsoft teams | ||
11/7/22 | PUW3/microsoft teams | ||
18/7/22 | PUW3/microsoft teams | Emma | Predicting antimicrobial susceptibility to blood culture results |
microsoft teams |
16/1/23 | PUW3/ microsoft teams | Soumya | PhD overview/viva practice |
23/1/23 | PUW3/microsoft teams | Shan | Adalimumab PKPD |
30/1/23 | PUW3/microsoft teams | Suzanne | Piperacillin-tazobactam PKPD |
6/2/23 | PUW3/microsoft teams | Vicky | PhD update |
13/2/23 | PUW3/microsoft teams | Ludo/Andrew | Modelling the effect of Antimicrobial use in poultry on AMR risk in 3 Asian countries / Optimized dosing regimens for the combinations of sulfonamides and trimethoprim in veterinary medicine |
20/2/23 | PUW3/microsoft teams | Hui | PhD update |
27/2/23 | PUW3/microsoft teams | Jude | Tacrolimus PKPD |
6/3/23 | PUW3/microsoft teams | ||
13/3/23 | PUW3/microsoft teams | Rachel | Project introduction |
20/3/23 | PUW3/microsoft teams | Najla | Systematic review |
27/3/23 | PUW3/microsoft teams | Emma | Antibiotic prescribing in remote versus face-to-face consultations for acute respiratory infections in English primary care: An observational study using TMLE |
17/4/23 | PUW3/microsoft teams | Vicky | Upgrade talk |
24/4/23 | PUW3/microsoft teams | Najla | Antimicrobial PKPD systematic review |
15/5/22 | PUW3/microsoft teams | Joe | Panoramic practice |
22/5/22 | PUW3/microsoft teams | Joe | FDA talk practice |
5/6/23 | PUW3/microsoft teams | Simone Perazzolo | Introduction to the SAAM2 software |
12/6/23 | PUW3/microsoft teams | Hui | PAGE meeting practice |
19/6/23 | PUW3/microsoft teams | Hui | PhD upgrade |
26/6/23 | PUW3/microsoft teams | PAGE | |
3/7/23 | PUW3/microsoft teams | WCP | |
10/7/23 | PUW3/microsoft teams | Rachel Clapham | PopPk of edoxaban |
PUW3/microsoft teams |
5/9/22 | PUW3/ microsoft teams | Jeff Barrett | Model-informed Pediatric Drug Development |
12/9/22 | PUW3/microsoft teams | Akosua | SARS-CoV-2 viral dynamics |
19/9/22 | PUW3/microsoft teams | ||
26/9/22 | PUW3/microsoft teams | Fan | Upgrade practice |
3/10/22 | PUW3/microsoft teams | Najla | Upgrade practice |
10/10/22 | PUW3/microsoft teams | Emma | Antibiotic prescribing and remote consultations in primary care |
17/10/22 | PUW3/microsoft teams | Ofran | TLMEs |
24/10/22 | PUW3/microsoft teams | Frank | ACoP practice |
31/10/22 | PUW3/microsoft teams | Reya | PKUK practice |
7/11/22 | PUW3/microsoft teams | All | ACoP/PKUK review |
14/11/22 | PUW3/microsoft teams | Jig | Fellowship chalkboard |
21/11/22 | PUW3/microsoft teams | ||
5/12/22 | PUW3/microsoft teams | Dolapo Odujinrin | Introduction to PhD project |
12/12/22 | PUW3/microsoft teams | ||
4/9/23 | PUW3/ microsoft teams | planning meeting | |
11/9/23 | PUW3/microsoft teams | Frank | TB modelling update |
18/9/23 | PUW3/microsoft teams | Zhara | Antimicrobial PKPD |
25/9/23 | PUW3/microsoft teams | Lizzy | Proposal overview |
2/10/23 | PUW1/microsoft teams | Jig Patel | Fellowship practice |
9/10/23 | PUW1/microsoft teams | Jan Stefan | NONMEM tips and tricks |
16/10/23 | PUW1/microsoft teams | Rob | Antimicrobial TDM Pro/con debate |
23/10/23 | PUW1/microsoft teams | Dolapo | Investigating mechanistic modelling approaches for individualised dosing of cancer therapeutics. |
30/10/23 | PUW1/microsoft teams | Fan | Ciclosporin |
6/11/23 | PUW1/microsoft teams | Joy | Neonatal sedative maturation functions |
13/11/23 | PUW1/microsoft teams | Oliver | CART preclinical modelling |
20/11/23 | PUW1/microsoft teams | Hui | Automated model building update |
27/11/23 | PUW1/microsoft teams | Lizzy | Rituximab PKPD |
4/12/23 | PUW1/microsoft teams | Najla | Systematic antimicrobial PKPD review |
11/12/23 | PUW1/microsoft teams | Andrew Mead | Update on antimicrobial PKPD |
8/1/24 | PUW3/ microsoft teams | planning meeting | |
15/1/24 | PUW3/ microsoft teams | Hui | Infection seminar |
22/1/24 | PUW1/microsoft teams | Charlotte | PhD plan |
29/1/24 | PUW3/microsoft teams | Martin Johnson | Machine learning in PKPD |
5/2/24 | PUW3/microsoft teams | Jude | Tacrolimus PK |
12/2/24 | PUW3/microsoft teams | ||
19/2/24 | microsoft teams | Shengyuan | Antiviral PKPD |
26/2/24 | microsoft teams | Vicky | NLP update |
4/3/24 | PUW3/microsoft teams | Oliver | CART update |
11/3/24 | PUW1/microsoft teams | Fan | Ciclosporin PK |
18/3/24 | PUW1/microsoft teams | Jig | Anticoagulant PKPD |
25/3/24 | PUW1/microsoft teams | Orlagh | NIHR outline |
8/4/24 | PUW1/microsoft teams | Planning meeting | |
15/4/24 | PUW1/microsoft teams | No meeting | |
22/4/24 | PUW1/microsoft teams | Hiie | Exenatide PKPD |
29/4/24 | PUW1/microsoft teams | Abigail | Preclinical antimicrobial PKPD |
13/5/24 | PUW1/microsoft teams | Charlotte T | BSTOP PKPD |
20/5/24 | PUW1/microsoft teams | Yawen | Vincristine PKPD |
3/6/24 | PUW1/microsoft teams | Vicky | NLP/PKPDai |
10/6/24 | PUW1/microsoft teams | Hui | nlmixr2auto |
17/6/24 | PUW1/microsoft teams | Shengyuan | PANORAMIC PD model |
24/6/24 | PUW1/microsoft teams | ||
1/7/24 | PUW1/microsoft teams | Andrew | Combination antimicrobial PKPD |
8/7/24 | PUW1/microsoft teams | Fan | Immunoglobulin PD |
2/9/24 | PUW3/ microsoft teams | planning meeting | |
9/9/24 | PUW3/ microsoft teams | Rohan Benecke | Metformin Dosing in Obese HIV patients |
16/9/24 | PUW3/microsoft teams | Paolo Denti | Importance of BOV |
23/9/24 | PUW3/microsoft teams | Hui | Update following UPSS |
30/9/24 | PUW?/microsoft teams | Rob | Vancomycin real time PK |
7/10/24 | PUW2/microsoft teams | Jude | Tacrolimus update |
14/10/24 | PUW1/microsoft teams | Hiie | Novel antimicrobial modelling approach |
21/10/24 | PUW1/microsoft teams | Charlotte | 5-FC update |
28/10/24 | PUW1/microsoft teams | Arwa | Drug-radiotherapy combinations |
4/11/24 | PUW1/microsoft teams | Vicky | Table extraction and PKPDAI update |
11/11/24 | PUW?/microsoft teams | PKUK practice | Yawen, Arwa, Shengyuan |
18/11/24 | PUW2/microsoft teams | Shengyuan | SARS-CoV-2 viral dynamics |
25/11/24 | PUW1/microsoft teams | Jig | RISAPS trial analysis |
2/12/24 | PUW2/microsoft teams | Najla | Amikacin PK in neonates |
9/12/24 | PUW2/microsoft teams | Yawen | Antimicrobial PKPD |
16/12/24 | PUW3/microsoft teams | Dolapo | Dose Selection Strategies for CAR-T Therapy in Oncology |